Prostaglandin H synthase Inhibitors
1 drugsAbout Prostaglandin H synthase
Prostaglandin H synthase, or cyclooxygenase (COX), is an enzyme involved in the biosynthesis of prostaglandins, thromboxanes, and prostacyclins. These signaling molecules mediate inflammation, pain, and fever.
Prostaglandin H synthase is a therapeutic target for pain management due to its role in inflammatory pathways. Currently, there is no genetic evidence directly linking Prostaglandin H synthase to specific diseases.
ILEVRO is the only FDA-approved drug targeting Prostaglandin H synthase, developed by HARROW EYE as a small molecule for pain relief. It was first approved in 2012.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Bladder Cancer with only 1 trials.
Top Prostaglandin H synthase Drugs
HARROW EYE is the only company with an approved drug targeting Prostaglandin H synthase.
Low competition suggests an opportunity for new entrants, but also indicates potential market challenges.
Prostaglandin H synthase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Prostaglandin H synthase, using small molecule modality.
Exploring alternative modalities like antibodies or biologics could provide differentiation.
Prostaglandin H synthase Clinical Trials 26 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 5 | 4 | 1 | 0 | 80% |
| Phase 3 | 7 | 6 | 1 | 0 | 86% |
| Phase 4 | 14 | 11 | 1 | 2 | 92% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Prostaglandin H synthase Drug Approval Timeline (2012 - 2012)
The first and only drug, ILEVRO, was approved in 2012.
The lack of recent approvals suggests market saturation or challenges in developing new therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 24 clinical trials targeting Prostaglandin H synthase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities